Administrative Core: Cellular and molecular mediators of fibrosis in the development of urinary tract dysfunction

管理核心：尿路功能障碍发展中纤维化的细胞和分子介质

• 批准号: 10264803
• 负责人: WILLIAM A RICKE
• 金额: $ 46.89万
• 依托单位: UNIVERSITY OF WISCONSIN-MADISON
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-09-24 至 2024-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10264803
• 关键词: 5 Alpha-Reductase Inhibitor; Adrenergic alpha-Antagonists; Affect; Aging; American; Animal Model; Area; Benign; Benign Prostatic Hypertrophy; Biomedical Research; Boston; Businesses; Cell model; Collaborations; Communication; Communities; Computer software; Consensus; Cost of Illness; Development; Discipline; Disease; Doctor of Philosophy; Ensure; Equipment; Faculty; Fibrosis; Functional disorder; Funding; Funding Opportunities; Future; Goals; Individual; Instruction; Lead; Leadership; Letters; Life; Link; Lower urinary tract; Mediator of activation protein; Medical; Mentored Clinical Scientist Development Program; Methods; Mission; Molecular; National Institute of Diabetes and Digestive and Kidney Diseases; Pathway interactions; Patients; Pharmaceutical Preparations; Population; Preclinical Testing; Production; Productivity; Prostate; Protocols documentation; Quality of life; Reproducibility; Research; Research Personnel; Research Training; Resources; SECTM1 gene; Scientific Societies; Scientist; Series; Services; Site Visit; Special Event; Students; Sum; Therapeutic; Tissue Model; Training; Training Programs; Translating; Universities; Urinary tract; Urology; Vision; Voice; Wisconsin; Work; antifibrotic treatment; cellular targeting; clinically relevant; cost; data dissemination; effectiveness research; experience; innovative technologies; lower urinary tract symptoms; meetings; member; new therapeutic target; next generation; organizational structure; outreach program; patient biomarkers; patient stratification; programs; symposium; urologic

PROJECT SUMMARY - ADMINISTRATIVE CORE The Administrative Core (Core A), has an overall mission to coordinate and successfully manage the UW- Madison O’Brien Research Center including UM-Boston and UT-Southwestern and lead benign urology research into the future. The overarching goal of the O’Brien Center for Benign Urology Research is to identify mechanisms that result in lower urinary tract dysfunction (LUTD) that result in benign prostatic hyperplasia (BPH) related lower urinary tract symptoms (LUTS). Criteria for successful completion are defined by the RFA 18-029 and include performing and disseminating outstanding benign urologic research, provide highly needed resources for the field, and provide outstanding educational enrichment while promoting the next generation of benign urology researchers. The Center targets new and exciting mechanisms of LUTD namely prostate fibrosis and translates it to clinically relevant therapeutics and biomarkers for patient stratification. BPH/LUTS can be life-threatening, affect quality of life, and is a costly disease, which NIDDK wants eradicate. Core A will achieve these goals by providing outstanding leadership, vision, and efficiency in the overarching administrative duties. The organization structure and leadership of Core A includes two outstanding investigators with recognized and complementary abilities in leading research groups and training programs. Dr. Ricke continues to serve as Core A director and will assume primary responsibility for day to day management and oversight of Core A. He will also be responsible for obtaining and managing the Opportunity Pool and maintain extensive interactions within the biomedical community. Dr. Vezina will serve as Associate Director for Core A and will direct the Educational Enrichment Program. Core A will interact with members of its external advisory board (EAB) and internal advisory board (IAB) on a semi-annual basis. All members or associated members of the center will be invited to partake in center functions including seminars, retreats, business meetings, and other special events. Drs. Ricke and Vezina meet with the NIDDK Executive Steering committee (ESC) and External Expert Panel (EEP) at NIDDK’s annual reverse site visit (see letter of reference Mark Nelson, PhD, ESC Chair). Their leadership and experience will allow us to promote interactions between our Center Projects, Core B, as well as other centers (U54, P20, K12) through: communication, collaboration, and coordination. Further interactions and data dissemination will occur in conjunction with the NIDDK’s O’Brien Center Interaction core, NIDDK program officials, American Urological Association Office of Research, scientific societies, and other venues. As directed by NIDDK, the benign urology research community has a viable focal point--The O’Brien Centers--in which to centralize ideas, research, resources, training, provide consensus, and offer a unified voice. The O’Brien Centers are more than the sum of parts, rather they provide leadership, synergize with researchers, and provide to the urology community above and beyond serving one’s own Center. Core A will lead this NIDDK shared vision.

项目摘要-行政核心 行政核心（核心A）的总体使命是协调和成功管理UW- 麦迪逊奥布莱恩研究中心，包括UM-波士顿和UT-西南和领导良性泌尿学研究 到未来。奥布莱恩良性泌尿外科研究中心的首要目标是确定 导致下尿路功能障碍（LUTD）的机制，导致良性前列腺增生（BPH） 相关下尿路症状（LUTS）。成功完成的标准由RFA 18 - 029定义 包括执行和传播优秀的良性泌尿学研究，提供高度需要的 资源的领域，并提供出色的教育丰富，同时促进下一代的 良性泌尿学研究者。该中心针对LUTD的新的和令人兴奋的机制，即前列腺纤维化 并将其转化为用于患者分层的临床相关疗法和生物标志物。BPH/LUTS可能是 危及生命，影响生活质量，是一种昂贵的疾病，NIDDK希望根除。核心A将实现 通过在总体行政职责中提供出色的领导力、远见和效率，实现这些目标。 核心A的组织结构和领导层包括两名杰出的调查员， 领导研究小组和培训项目的互补能力。Ricke博士继续担任核心 一名董事，主要负责核心A的日常管理和监督。他将 还负责获取和管理机会池并保持内部的广泛互动 生物医学界。Vezina博士将担任核心A的副主任，并将指导教育 强化计划。核心A将与其外部咨询委员会（EAB）和内部咨询委员会的成员互动， IAB（IAB），每半年一次。中心的所有会员或相关会员将被邀请参加 在中心的功能，包括研讨会，务虚会，商务会议和其他特殊活动。Ricke博士和 Vezina会见NIDDK执行指导委员会（ESC）和外部专家小组（EEP） 年度反向研究中心访视（参见推荐信Mark纳尔逊，PhD，ESC主席）。他们的领导能力和经验 将使我们能够促进我们的中心项目，核心B，以及其他中心（U54，P20， K12）通过：沟通，协作和协调。进一步的互动和数据传播将 与NIDDK的奥布莱恩中心互动核心一起发生，NIDDK计划官员，美国 泌尿外科协会研究办公室、科学学会和其他场所。根据NIDDK的指示， 良性泌尿学研究团体有一个可行的焦点--奥布莱恩中心--在那里集中思想， 研究，资源，培训，提供共识，并提供统一的声音。奥布莱恩中心 部分的总和，而不是他们提供领导，与研究人员协同，并提供给泌尿科 超越自我，服务于自己的中心。核心A将引领NIDDK的共同愿景。